In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Participants will get treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. General, our present-day work highlights the potential utilization of ARV-825 in https://abbv-744preclinicalstudie57807.blogvivi.com/32518431/the-smart-trick-of-abbv-744-preclinical-studies-and-results-that-nobody-is-discussing